Alnylam identifies gene target for potential novel therapy for cardiovascular and metabolic disorders, says GlobalData
August 18, 2022 (Investorideas.com Newswire) Alnylam Pharmaceuticals and its partners have identified rare mutations in the INHBE gene that is expressed in the liver and related to a lower waist-to-hip ratio for body mass index (BMI) reducing the likelihood of many major metabolic disorders. With such high levels of interest preventing metabolic disorders, it is likely that a drug which holds a capacity to demonstrate high efficacy in targeting INHBE expression will gain a significant market share as it could help in reducing the risk significantly for multiple metabolic disorders, says GlobalData, a leading data and analytics company.
Using the UK Biobank, Alnylam was able to search gene variants that were associated with lower waist-to-hip ratio adjusted for BMI, which is often used as an indicator of abdominal fat and is correlated to risk of type 2 diabetes (T2D) and coronary heart disease, and identified that the mutated INHBE gene can be found in 1 in 587 individuals. The company plans to leverage its RNAi platform to develop a pipeline candidate that targets INHBE and Activin E.
Akash Patel, Pharma Analyst at GlobalData, comments: "There is a significantly increasing body of evidence relating obesity to T2D and related metabolic disorders such as coronary heart disease and heart failure (HF). Several therapies have emerged in the last five to 10 years, particularly in the glucagon-like peptide-1 receptor agonist (GLP-1) class, that address obesity and decrease cardiovascular risk in addition to leading to improved HbA1c for patients with T2D."
In particular, semaglutide (Rybelsus and Ozempic) from Novo Nordisk and tirzepatide (Mounjaro) from Eli Lilly have rapidly become the market-leading therapies for patients with T2D and obesity.
Patel adds: "As the late-stage clinical studies have shown Mounjaro has the ability to transform the treatment of obesity, in addition to T2D. The drug will likely be prescribed in combination with other therapies to address additional cardiorenal problems and will progress to becoming a leading GIP/GLP-1 therapy. Furthermore, trials for pediatric patients and heart failure patients are currently ongoing, which will also strengthen Lilly’s position across the wider T2D and cardiometabolic market."
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
Notes to Editors
- Quotes provided by Akash Patel, Pharma Analyst at GlobalData
4,000 of the world's largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData's unique data, expert analysis and innovative solutions, all in one platform. GlobalData's mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/